Elisabeth Turpin

Summary

Country: France

Publications

  1. pmc The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma
    Ghada Kchour
    Immunology Research Centre Bu Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
    Retrovirology 10:91. 2013
  2. pmc Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers
    Jacqueline Lehmann-Che
    INSERM CNRS University Paris 7, UMR 944 7212, Hopital Saint Louis, 1, Av Claude Vellefaux, 75 475 Paris Cedex 10, France
    Oncologist 15:246-52. 2010

Collaborators

  • Ghada Kchour
  • Hugues De The
  • Jacqueline Lehmann-Che
  • Abbas Shirdel
  • Hossein Rahimi
  • Mahdi Tarhini
  • Mahmoud Mahmoudi
  • Ali Bazarbachi
  • Zeina Dassouki
  • Mohamad Ezzedine
  • Fadwa Berry
  • Akram Ghantous
  • Mohamad Mehdi Kooshyar
  • Reza Farid
  • Ardeshir Ghavamzadeh
  • Olivier Hermine
  • Roudaina Nasser
  • Hiba El Hajj
  • Mohamad Mortada
  • Houshang Rafatpanah
  • Sa Rahim Rezaee
  • Michel Marty
  • W Fraser Symmans
  • Louis Fran├žois Plassa
  • Fabrice Andre
  • Christine Desmedt
  • Philippe Bertheau
  • Sylvie Giacchetti
  • Lajos Pusztai
  • Marc Espie
  • Chafika Mazouni
  • Christos Sotiriou
  • Martine Piccart

Detail Information

Publications2

  1. pmc The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma
    Ghada Kchour
    Immunology Research Centre Bu Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
    Retrovirology 10:91. 2013
    ..The combination of zidovudine and interferon-alpha (IFN) significantly improved survival in ATL. Promising results were reported by adding arsenic trioxide to zidovudine and IFN...
  2. pmc Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers
    Jacqueline Lehmann-Che
    INSERM CNRS University Paris 7, UMR 944 7212, Hopital Saint Louis, 1, Av Claude Vellefaux, 75 475 Paris Cedex 10, France
    Oncologist 15:246-52. 2010
    ..The latter allowed very high levels of pCR in triple-negative tumors. Thus, our data strongly suggest that cyclophosphamide dose intensification in ER(-) p53-mutated breast cancer patients could significantly improve their response...